Loading…
Amylyx Pharmaceuticals, Inc. is projected to rise to $29.23 by 2027, a +41% move from its current price of $20.75. AMLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $20.18 | $20.77 | $21.37 | +0.09% |
| Aug 2 | $19.97 | $20.79 | $21.65 | +0.19% |
| Aug 3 | $19.80 | $20.81 | $21.86 | +0.28% |
| Aug 4 | $19.67 | $20.83 | $22.05 | +0.38% |
| Aug 5 | $19.56 | $20.85 | $22.22 | +0.47% |
| Aug 6 | $19.46 | $20.87 | $22.38 | +0.57% |
| Aug 7 | $19.37 | $20.89 | $22.53 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.37 | $20.89 | $22.53 | +0.66% |
| Week 2 | $18.89 | $21.03 | $23.40 | +1.33% |
| Week 3 | $18.57 | $21.17 | $24.13 | +2.00% |
| Week 4 | $18.32 | $21.31 | $24.78 | +2.68% |
| Week 5 | $18.11 | $21.45 | $25.40 | +3.36% |
| Week 6 | $17.94 | $21.59 | $25.98 | +4.05% |
| Week 7 | $17.79 | $21.73 | $26.55 | +4.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX is currently trading at $20.75 with a market cap of $2.31B, and it is ranked 1811 by market cap. The current price sits amid a forecast that shows limited downside in 2026 with an average price of $20.75 and a neutral sentiment, followed by substantial long-term upside into 2030 and beyond. The 30-year forecast trajectory suggests meaningful appreciation, culminating in an average of $55.27 by 2030 and $457.71 by 2050, with a max of $860.36 in 2050.
The 2026 forecast range is $11.38 to $30.43, with an average of $20.75 and ROI of 0%, reflecting a neutral near-term view. From 2027 onward, the outlook strengthens, with the average price rising to $29.23 in 2027 and to $55.27 by 2030, while the max expands to $81.04 in 2030.
Longer horizon forecasts show continued upside, with 2031 at an average of $64.37 and 2032 at $72.84; 2033 at $85.21 and 2034 at $112.93; 2035 at $124.99. In the 2040s, the average price is projected to $215.35, and by 2050 the average is $457.71 with a max of $860.36, accompanied by rising bullish sentiment across the period.
A major floor 38.6% below — a decisive break under it would weaken the trend.
The nearest floor, 26.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 17.7% above — clearing it would confirm fresh momentum.
Key AMLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.59 | Buy | $19.67 | Buy |
| MA 10 | $18.69 | Buy | $19.03 | Buy |
| MA 20 | $18.29 | Buy | $18.32 | Buy |
| MA 50 | $16.27 | Buy | $17.06 | Buy |
| MA 100 | $15.80 | Buy | $16.03 | Buy |
| MA 200 | $14.80 | Buy | $14.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.04 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 241.66 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 14.01 | Buy |
| Bollinger %B (20,2) | 1.18 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.62 | Buy |
| Awesome (5,34) | 2.09 | Buy |
| Ultimate (7,14,28) | 73.32 | Sell |
| Momentum (10) | 3.73 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 20.43 | Buy |
| ADX (14) | 23.42 | Buy |
| ATR (14) | 0.54 | Info |
The 30-day picture shows bullish near-term momentum, with RSI14 at 70 and the price trading above both the SMA50 of $16.27 and the SMA200 of $14.80, signaling a positive trend. The 30-day range spans $17.19 to $25.05, while support is at $15.25 and resistance at $20.75, placing the current price of $20.75 near a key level.
Overall near-term dynamics point to continued upside potential if price can clear the $20.75 resistance, though RSI at the 70 level suggests momentum could temper if the level proves tough to sustain.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.38 | $20.75 | $30.43 | 0% | Neutral | |
| $23.21 | $29.23 | $38.98 | +41% | Bullish | |
| $32.38 | $42.00 | $58.24 | +102% | Bullish | |
| $39.70 | $52.78 | $75.44 | +154% | Bullish | |
| $40.68 | $55.27 | $81.04 | +166% | Bullish | |
| $46.45 | $64.37 | $96.49 | +210% | Bullish | |
| $51.61 | $72.84 | $111.38 | +251% | Bullish | |
| $59.34 | $85.21 | $132.65 | +311% | Bullish | |
| $77.37 | $112.93 | $178.72 | +444% | Bullish | |
| $84.30 | $124.99 | $200.85 | +502% | Bullish | |
| $135.25 | $215.35 | $368.91 | +938% | Bullish | |
| $254.09 | $457.71 | $860.36 | +21.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.38 | $20.75 | $24.24 | +0.00% |
| August 2026 | $18.91 | $22.22 | $26.72 | +7.07% |
| September 2026 | $19.08 | $22.62 | $27.59 | +1.80% |
| October 2026 | $19.03 | $22.71 | $28.01 | +0.40% |
| November 2026 | $19.70 | $23.65 | $29.43 | +4.14% |
| December 2026 | $20.10 | $24.26 | $30.43 | +2.58% |
Click any year to see its month-by-month AMLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AMLX could reach as high as $30.43, with a base case around $20.75 and support toward $11.38 — roughly 0% from $20.75. A consolidation phase looks the most probable path here.
Expect AMLX to range from $23.21 to $38.98 through 2027. The $29.23 average target implies a +41% move from current prices. That is up +41% on the projected 2026 average. Momentum favours further upside here.
The AMLX price prediction for 2028 points to an average of $42.00 (low $32.38, high $58.24) — a potential gain of +102% on today's $20.75. Buyers look set to stay in control over this stretch.
In 2029, AMLX is projected to trade between $39.70 and $75.44, averaging $52.78 — a potential gain of +154% from today's $20.75. That is up +26% on the projected 2028 average. Momentum favours further upside here.
Amylyx Pharmaceuticals, Inc.'s 2030 outlook centres on $55.27, within a $40.68 to $81.04 range. That is up +5% on the projected 2029 average. That marks a +166% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, AMLX could reach as high as $96.49, with a base case around $64.37 and support toward $46.45 — roughly +210% from $20.75. Momentum favours further upside here.
Expect AMLX to range from $51.61 to $111.38 through 2032. The $72.84 average target implies a +251% move from current prices. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The AMLX price prediction for 2033 points to an average of $85.21 (low $59.34, high $132.65) — a potential gain of +311% on today's $20.75. Momentum favours further upside here.
In 2034, AMLX is projected to trade between $77.37 and $178.72, averaging $112.93 — a potential gain of +444% from today's $20.75. That is up +33% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Amylyx Pharmaceuticals, Inc.'s 2035 outlook centres on $124.99, within a $84.30 to $200.85 range. That is up +11% on the projected 2034 average. That marks a +502% change versus current levels. Momentum favours further upside here.
By 2040, AMLX could reach as high as $368.91, with a base case around $215.35 and support toward $135.25 — roughly +938% from $20.75. Buyers look set to stay in control over this stretch.
Expect AMLX to range from $254.09 to $860.36 through 2050. The $457.71 average target implies a +21.1x move from current prices. That is up +113% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AMLX today (≈ 48.192771 AMLX) could be worth
$22,058.46
+$21,058.46 (+2106%) by 2050 · US Dollar
Based on the average projected AMLX price of $457.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMLXwould be worth at today's price.
$1,000 invested in AMLX on Jul 30, 2025 (≈ 125.470518 AMLX) would be worth
$2,603.51
+$1,603.51 (+160.4%) today · 2.60× · US Dollar
Based on a AMLX entry price of $7.97 vs. today's $20.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.59 | $1,179.65 | +18.0% |
| 1 month ago | $17.96 | $1,155.35 | +15.5% |
| 3 months ago | $16.01 | $1,296.06 | +29.6% |
| 6 months ago | $14.29 | $1,452.06 | +45.2% |
| 1 year ago | $7.97 | $2,603.51 | +160.4% |
| All time (4.6y) ago | $18.07 | $1,148.31 | +14.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMLX forecast.
Our base-case forecast reaches $42.00 around 2028.
Implied market cap at $42.00: $4.67B
The multi-year forecast depicts a pronounced upside trajectory. In 2026 the average price is $20.75 with a min of $11.38 and a max of $30.43, and ROI of 0 with a neutral sentiment. By 2027, the average rises to $29.23 (min $23.21, max $38.98) and ROI 40.9 with bullish sentiment.
The path continues higher through 2028 at $42.00, 2029 at $52.78, and 2030 at $55.27 (min $40.68, max $81.04; ROI 166.4).
From 2031 onward, the forecast shows substantial growth: 2031 average $64.37 (min $46.45, max $96.49; ROI 210.2), 2032 average $72.84 (min $51.61, max $111.38; ROI 251.1), 2033 average $85.21 (min $59.34, max $132.65; ROI 310.6), 2034 average $112.93 (min $77.37, max $178.72; ROI 444.2), and 2035 average $124.99 (min $84.30, max $200.85; ROI 502.4) with bullish sentiment.
In the long arc, 2040 shows an average of $215.35 (min $135.25, max $368.91; ROI 937.8), and by 2050 the average is $457.71 (min $254.09, max $860.36; ROI 2105.8) with strong bullish sentiment. These figures illustrate substantial, though uncertain, upside potential across the extended horizon.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $55.27 with a range from $40.68 to $81.04, and ROI of 166.4% with bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward, with the average price rising from $29.23 in 2027 to $55.27 in 2030 and continuing higher to $457.71 by 2050, though these are estimates and not guarantees.
Yes, the forecast max by 2033 is $132.65, and by 2034 it is $178.72, indicating a potential move above $100 in the mid-2030s.
The 30-day range is $17.19 to $25.05, current price is $20.75, RSI14 is 70, and price sits above the SMA50 ($16.27) and SMA200 ($14.80) with support at $15.25 and resistance at $20.75.
Long-term forecasts show rising averages: 2030 $55.27, 2040 $215.35, and 2050 $457.71, with a max of $860.36 in 2050 and bullish sentiment, acknowledging these are projections and not guarantees.
Amylyx Pharmaceuticals, Inc. Community Discussion
0Share your Amylyx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.